Literature DB >> 9758594

Mixed messages: presentation of information in cystic fibrosis-screening pamphlets.

G L Loeben1, T M Marteau, B S Wilfond.   

Abstract

Written pamphlets are an important source of information for individuals deciding whether to undergo carrier testing for cystic fibrosis (CF). Adequate understanding of the condition and reproductive options following the diagnosis of a fetus with CF are critical to informed decision making. The information given about CF and reproductive options in 28 pamphlets about carrier testing, from commercial and noncommercial organizations in the United States and the United Kingdom, aimed at prenatal and other populations, was assessed. The amount of information provided about CF showed a range of 1-37 sentences (median 6.5), with most being relatively neutral and with a minority conveying a positive or a negative image. Positive sentences were less common in British, U.S. commercial, and prenatal pamphlets. Statements about life expectancy also varied considerably, both in the ages provided and in the degree of optimism conveyed. In addition, the pamphlets varied in the amount of information they provided about reproductive options following the diagnosis of a fetus with CF. Abortion was mentioned in just 15 pamphlets, more often in the United Kingdom than in the United States and more frequently in pamphlets from noncommercial than in those from commercial organizations. Wide variation in the descriptions of CF and the reproductive options presented raises concerns about the extent to which any one pamphlet may present balanced information. The choices about what information to include in educational materials need to be explicitly considered on the basis of the message intended to be sent.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Year:  1998        PMID: 9758594      PMCID: PMC1377469          DOI: 10.1086/302036

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  7 in total

1.  Community involvement in developing policies for genetic testing: assessing the interests and experiences of individuals affected by genetic conditions.

Authors:  Sarah E Gollust; Kira Apse; Barbara P Fuller; Paul Steven Miller; Barbara B Biesecker
Journal:  Am J Public Health       Date:  2005-01       Impact factor: 9.308

2.  Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening.

Authors:  Francis A M Poppelaars; Herman J Adèr; Martina C Cornel; Lidewij Henneman; Rosella P M G Hermens; Gerrit van der Wal; Leo P ten Kate
Journal:  J Genet Couns       Date:  2004-02       Impact factor: 2.537

3.  Development of an evidence-based information booklet to support parents of children without a diagnosis.

Authors:  Celine Lewis; Heather Skirton; Ray Jones
Journal:  J Genet Couns       Date:  2012-04-21       Impact factor: 2.537

4.  'Balance' is in the eye of the beholder: providing information to support informed choices in antenatal screening via Antenatal Screening Web Resource.

Authors:  Shenaz Ahmed; Louise Bryant; Jenny Hewison
Journal:  Health Expect       Date:  2007-12       Impact factor: 3.377

5.  Decisions about testing and termination of pregnancy for different fetal conditions: a qualitative study of European White and Pakistani mothers of affected children.

Authors:  Shenaz Ahmed; Jenny Hewison; Josephine M Green; Howard S Cuckle; Janet Hirst; Jim G Thornton
Journal:  J Genet Couns       Date:  2008-10-09       Impact factor: 2.537

6.  Presenting life with cystic fibrosis: a Q-methodological approach to developing balanced, experience-based prenatal screening information.

Authors:  Katherine F Wright; Louise D Bryant; Stephen Morley; Jenny Hewison; Alistair J A Duff; Daniel Peckham
Journal:  Health Expect       Date:  2013-08-02       Impact factor: 3.377

7.  Framing optional genetic testing in the context of mandatory newborn screening tests.

Authors:  Sarah E Lillie; Beth A Tarini; Nancy K Janz; Brian J Zikmund-Fisher
Journal:  BMC Med Inform Decis Mak       Date:  2015-06-27       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.